05/26/22 6:00 AMNasdaq : INCY Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual MeetingIncyte today announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 Congress. “We are committed to advancing science that can lead to solutions for patients with serious unmet medical needs, including those with cancer,” said Steven Stein, M.D., Chief Medical...RHEA-AIneutral
05/24/22 8:00 AMNasdaq : INCY conferencesIncyte to Present at Upcoming Investor ConferenceIncyte announced today that it will present at the 43 rd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 14, 2022 at 8:00 a.m./ 11 a.m. in Rancho Palos Verdes. Incyte is a Wilmington, Delaware- based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and...RHEA-AIneutral
05/20/22 8:11 AMNYSE, Nasdaq : LLY, INCY CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for OLUMIANT ® (baricitinib) for the treatment ofRHEA-AIneutral
05/11/22 6:45 AMNYSE, Nasdaq : LLY, INCY fda approvalcovid-19FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today the U.S. FoodRHEA-AIvery positive
05/05/22 1:20 AMNasdaq : INCY Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host DiseaseIncyte today announced the European Commission has approved Jakavi ® for the treatment of patients aged 12 years and older with acute or chronic GVHD who have inadequate response to corticosteroids or other systemic therapies. Ruxolitinib is marketed as Jakavi by Novartis in Europe and as Jakafi ® by Incyte in the United States. “With the approval of this...RHEA-AIpositive
05/04/22 4:15 PMNasdaq : INCY conferencesIncyte to Present at Upcoming Investor ConferenceIncyte announced today that it will present at the 2022 RBC Capital Markets Healthcare Conference on Tuesday, May 17, 2022 at 10:30 a.m. ET in New York. About Incyte Incyte is a Wilmington, Delaware- based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization...RHEA-AIneutral
05/03/22 7:00 AMNasdaq : INCY earningsIncyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsIncyte today reports 2022 first quarter financial results, and provides a status update on the Company’ s clinical development portfolio. “Our double-digit growth in the first quarter reflects the strong performance of Jakafi ®– supported by the successful launch in chronic graft-versus-host disease in the United States– as well as continued growth for...RHEA-AIpositive
04/28/22 4:05 PMNasdaq : INCY Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in JapanIncyte and Maruho Co., Ltd. today announced that the companies have entered into a Strategic Alliance Agreement for the development, manufacturing and exclusive commercialization of ruxolitinib cream, a novel cream formulation of Incyte’ s selective JAK2 inhibitor ruxolitinib, for treatment of autoimmune and inflammatory...RHEA-AIvery positive
04/22/22 9:40 AMNasdaq : INCY Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung CancerIncyte today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency’ s has issued a positive opinion that recommends granting marketing authorization for capmatinib as a monotherapy for the treatment of adults with advanced non-small cell lung cancer harboring alterations leading to...RHEA-AIneutral
04/12/22 8:00 AMNasdaq : INCY conferencesearningsIncyte to Report First Quarter Financial ResultsIncyte announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 3, 2022. Incyte is a Wilmington, Delaware- based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of...RHEA-AIneutral